WHITEPAPER | PRECISION MEDICINE IN CNS DRUG DEVELOPMENT

Precision Medicine in CNS Drug Development

By Daniel Klamer, PhD, Anavex Life Sciences Corp.

Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled precision medicine to become a more viable treatment option. The next frontier in this type of medicine may be in the treatment of central nervous system disorders.

This whitepaper evaluates the following:  

  • What lessons can we learn from the use of precision medicine in oncology?
  • How has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s?
  • What questions should you ask before you add a new biomarker to your clinical trial?
  • What are the pros and cons of using biomarkers as surrogate endpoints?

VIEW THE
WHITEPAPER

ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives organizations of all sizes in all industries the confidence to simply and securely share sensitive documents with third parties during due diligence, fundraising, board communications, and any circumstance when it is crucial that confidential information is maintained under the highest level of security and control.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.